Ph.D. Supervisor, Doctor of Medicine, Chief Physician, Professor. First group of academic and technical leaders in Anhui Province, recipient of special government allowances from the State Council and the provincial government.
Education and Work Experience
- 1979-1984: Bachelor’s in Clinical Medicine, Wannan Medical College
- 1986-1989: Master’s in Microbiology, Bengbu Medical College
- 2006-2009: Ph.D. in Pharmacology, Anhui Medical University
- 1984-1986: Teaching Assistant, Microbiology Department, Wannan Medical College
- 1989-Present: Laboratory Department, First Affiliated Hospital of the University of Science and Technology of China
Academic Achievements and Impact
Focused on the antitumor effects of bacterial toxins and research on bacterial resistance and pathogenicity for many years. Supervised over 40 doctoral and master’s students. Led more than 10 national and provincial natural science foundation projects, won one first prize, two second prizes, and two third prizes for provincial scientific and technological progress. Published over 160 papers, including more than 40 SCI papers. Authored or co-authored six books.
Ongoing Projects (Main Leader Only)
1. Study on the Role and Mechanism of Staphylococcal PV Leukocidin S Component Targeting C5aR in Downregulating HDAC6 to Inhibit Epithelial-Mesenchymal Transition in Liver Cancer Cells, National Natural Science Foundation, 5.5 million RMB, 2020.01 to 2023.12
2. Study on the Role and Mechanism of VraSR in Pathogenicity of Low-Level Vancomycin-Resistant Staphylococcus aureus, National Natural Science Foundation, 5.6 million RMB, 2018.01 to 2021.12
Main Research Areas (Recruitment Fields) and Content
Clinical Medicine
1. Clinical Laboratory Diagnostics
- Antitumor effects of bacterial toxins
- Research on bacterial resistance and pathogenicity
Representative Papers (Last Five Years)
1. Tao W, Wang X, Zhang G, et al. Re-detectable positive SARS-CoV-2 RNA tests in patients who recovered from COVID-19 with intestinal infection. Protein Cell. 2020.
2. Ma H, Zeng W, He H, et al. Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunol. 2020.
3. Wang Z, Yu W, Qiang Y, et al. LukS-PV Inhibits Hepatocellular Carcinoma Progression by Downregulating HDAC2 Expression. Mol Ther Oncolytics. 2020.
4. Dai Y, Gao C, Chen L, et al. Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Uses the VraSR Regulatory System. Front Microbiol. 2019.
5. Yang Q, Zhou Y, Ai J, et al. Collaborated effort against SARS-CoV-2 outbreak in China. Clin Transl Med. 2020.
Contact Information
Email: maxiaoling@ustc.edu.cn
Phone: 13955168613